The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted Cipla Limited ...

Tom Nolan reviews this week’s research Cannabinol—aka CBD—is a modern day tonic for almost any ailment, available in all good vape shops and petrol stations. In 2023, the Food Standards Agency cut the ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksTh ...

The Saudi Arabia cough suppressant drugs market reflects a dynamic landscape shaped by various factors such as evolving consumer preferences, advancements in pharmaceutical research, and regulatory ...

If you’re having trouble breathing or sleeping, you’re not alone—and there’s help available. As a pulmonologist and sleep ...

The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.